Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04860986
Other study ID # CLN-1001-001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 7, 2021
Est. completion date November 17, 2021

Study information

Verified date November 2023
Source EarliTec Diagnostics, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study is a prospective randomized repeatability and reproducibility (R&R) study of the EarliPoint DeviceTM in pediatric subjects 16-30 months of age. The study will enroll subjects who are both clinically-positive and clinically-negative for ASD. The study will be conducted at a single center in the US. The Study consists of a screening period in order to review the subject's medical history to determine subject eligibility, followed by a device administration period during which subjects will undergo testing with the EarliPoint Devices and Expert Clinician Diagnosis (ECD) procedures to determine if they are clinically-positive or clinically-negative for ASD.


Description:

Subjects will undergo testing with the same two (2) devices, with one (1) testing session per device per subject, with each testing session yielding three (3) measurements per endpoint per subject, for a total of six (6) measurements per endpoint for each subject enrolled. The order in which the subjects receive testing with each device will be randomized so that the same device is not always used first or last for each subject. The primary objectives of this study are to quantify the repeatability variability and reproducibility variability of all of the EarliPoint device's continuous valued outputs: the underlying continuous score used to classify patients into the binary diagnostic classification of either clinically-positive or clinically-negative for autism spectrum disorder (ASD) as well as each of the three EarliPoint Device severity scores (the social disability index, verbal ability index, and nonverbal ability index). The secondary objectives of this study are to quantify the repeatability and reproducibility variability in producing each of the three EarliPoint Device severity scores: the social disability index, verbal ability index, and nonverbal ability index.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date November 17, 2021
Est. primary completion date November 17, 2021
Accepts healthy volunteers No
Gender All
Age group 16 Months to 30 Months
Eligibility Inclusion Criteria: - Children between 16 and 30 months of age. - No acute illnesses by physical observation. - Normal or corrected-to-normal vision, and normal or corrected-to-normal hearing. - Communicate meaningfully with patent in English, and the principal investigator /the study team. - Parent or legal guardian is able to read and understand the Informed Consent Form. - Parent voluntarily provides written informed consent. Exclusion Criteria: - Genetic disorders (e.g., Fragile X, Williams Syndrome, Tuberous Sclerosis, muscular Dystrophy, Neurofibromatosis, Down Syndrome). - History or presence of a clinically significant medical disease or a mental state that might confound the study result as assessed by the investigator, such as severe hearing or visual impairment; or uncontrolled epilepsy or seizure disorder, et al. - Acute exacerbations of chronic illnesses likely to prevent successful data collection. - Receiving therapies that may affect vision. - Therapies that may affect the ability to focus. - Known allergies or sensitivity to the plastic, leather, or metal components. - Unable or unwilling to sit in a child safety seat. - Use of any investigational drug, therapies or diagnostic device within the past 14 days.

Study Design


Intervention

Device:
EarliPoint
EarliPoint is a non-invasive diagnostic device for ASD

Locations

Country Name City State
United States Emory University Atlanta Georgia

Sponsors (1)

Lead Sponsor Collaborator
EarliTec Diagnostics, Inc

Country where clinical trial is conducted

United States, 

References & Publications (2)

Jones W, Klaiman C, Richardson S, Aoki C, Smith C, Minjarez M, Bernier R, Pedapati E, Bishop S, Ence W, Wainer A, Moriuchi J, Tay SW, Klin A. Eye-Tracking-Based Measurement of Social Visual Engagement Compared With Expert Clinical Diagnosis of Autism. JAMA. 2023 Sep 5;330(9):854-865. doi: 10.1001/jama.2023.13295. — View Citation

Jones W, Klaiman C, Richardson S, Lambha M, Reid M, Hamner T, Beacham C, Lewis P, Paredes J, Edwards L, Marrus N, Constantino JN, Shultz S, Klin A. Development and Replication of Objective Measurements of Social Visual Engagement to Aid in Early Diagnosis and Assessment of Autism. JAMA Netw Open. 2023 Sep 5;6(9):e2330145. doi: 10.1001/jamanetworkopen.2023.30145. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The EarliPoint Device repeatability EarliPoint Device repeatability agreement in producing binary diagnostic outcomes (clinically-positive or negative for ASD) between multiple measurements per subject conducted with the same device (i.e., intra-device agreement);classification of either clinically-positive or clinically-negative for autism spectrum disorder (ASD) as well as each of the three EarliPoint Device severity scores (the social disability index, verbal ability index, and nonverbal ability index). Anticipated in about 6 months
Primary The EarliPoint Device reproducibility EarliPoint Device reproducibility agreement in producing binary diagnostic outcomes (clinically-positive or negative for ASD) between single measurements per subject conducted with multiple devices (i.e., inter-device agreement); Anticipated in about 6 months
Primary The repeatability variance of the underlying EarliPoint Device Repeatability variance of the underlying EarliPoint Device ASD presence metric (this metric is a continuous score underlying the binary diagnostic outcome: values less than or equal to 0 indicate a patient has ASD [clinically-positive], values greater than 0 indicate a patient does not have ASD [clinically-negative]); Anticipated in about 6 months
Primary The reproducibility variance of the underlying EarliPoint Device reproducibility variance of the underlying EarliPoint Device ASD presence metric (this metric is a continuous score underlying the binary diagnostic outcome: values less than or equal to 0 indicate a patient is ASD positive, values greater than 0 indicate a patient is ASD negative). Anticipated in about 6 months
See also
  Status Clinical Trial Phase
Terminated NCT03715166 - Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder Phase 3
Not yet recruiting NCT05182697 - SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD) N/A
Completed NCT02803801 - Build Your Parenting Toolkit: Guiding Children to Become Flexible Thinkers N/A
Recruiting NCT04376151 - Guided ACT and for Adults With ASD N/A
Terminated NCT03715153 - Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. Phase 3
Terminated NCT01592773 - Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Phase 2
Withdrawn NCT01395953 - Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders Phase 2
Terminated NCT01248130 - Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders Phase 2
Active, not recruiting NCT04299464 - A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) Phase 2
Recruiting NCT03392870 - Evaluation of a Clinical Transitional Program in Autism N/A
Completed NCT01592786 - An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Phase 2
Enrolling by invitation NCT05187377 - A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism Phase 2
Completed NCT04631432 - Choice Switching and Autism
Recruiting NCT04578756 - Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder Phase 3
Completed NCT02037022 - Pivotal Response Treatment Package for Young Children With Autism N/A
Completed NCT01854346 - Social Skills Group Training ("KONTAKT") for Children and Adolescent With High-functioning Autism Spectrum Disorders N/A
Active, not recruiting NCT04895215 - AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) Phase 2
Active, not recruiting NCT03426826 - The Gut-Brain Study Phase 1
Completed NCT02384486 - Efficacy of Training Programme to Reduce Stress N/A
Completed NCT00614198 - ScanBrit Dietary Intervention in Autism Phase 2